HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), has entered into a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC, a prominent neuropsychiatry clinic based in western Florida. This strategic move is anticipated to immediately contribute to HOPE Therapeutics' revenue and EBITDA, reinforcing its position in the interventional psychiatry market.
Cohen and Associates, located in the Sarasota-Bradenton area, specializes in advanced treatments for mood disorders, PTSD, and suicidal depression, including ketamine infusions and transcranial magnetic stimulation (TMS). The clinic, under the leadership of Dr. Rebecca Cohen, is recognized for its comprehensive psychiatric care services.
This acquisition is a cornerstone for HOPE Therapeutics' ambitious plan to expand its network to 30 clinics, aiming for a $100 million run rate by the end of 2025. The partnership with Cohen and Associates not only enhances HOPE's service offerings but also solidifies its footprint in Florida's competitive healthcare landscape.
For further details on NRx Pharmaceuticals and its subsidiaries, investors can visit the company's newsroom at https://ibn.fm/NRXP.
